Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11905525B2 · kind B2 · utility
13Cited by
59References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2018 |
| Grant date | Feb 20, 2024 |
| Priority date | — |
| Expiry date | Apr 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering nucleic acids in vivo. These compositions have reduced immune activation resulting in accelerated blood clearance and/or anti-drug antibodies and they have an improved toxicity profile and therapeutic index in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.